# US 8,771,963 B2 · Method of diagnosing esophageal cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,771,963 B2 - Document ID: US8771963B2 - Status: Granted - Kind: B2 - Application number: 13/246,639 - Filed: 2011-09-27 - Published: 2012-01-26 - Granted: 2014-07-08 - Earliest claimed: 2005-07-27 - Assignees: Oncotherapy Science, Inc. - Applicants: Yusuke Nakamura; Yataro Daigo; Shuichi Nakatsuru - Inventors: Yusuke Nakamura; Yataro Daigo; Shuichi Nakatsuru - Web page: https://patentgrep.com/patent/US8771963B2 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 35/04: specific for metastasis - C12Q 2600/118: Prognosis of disease development - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/158: Expression markers - Y10T 436/25: including sample preparation - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. ## Claims ### Claim 1 A method for diagnosing cancer in a subject, comprising the steps of: (a) collecting a blood sample from a subject suspected to be suffering from an esophageal cancer or lung cancer expressing DKK1 protein; (b) determining a level of DKK1 protein in the blood sample; (c) comparing the DKK1 protein level determined in step (b) with that of a normal control obtained from a population not suffering from cancer; and (d) judging that a DKK1 protein level in the blood sample which is at least 10% higher than the normal control indicates that the subject suffers from esophageal cancer or lung cancer; and (e) providing a diagnosis for a choice of treatment if the DKK1 protein level indicates that the subject suffers from esophageal cancer or lung cancer, wherein the diagnosis has a sensitivity of 63.7% and a specificity of 95.9%. ### Claim 2 (depends on 1) The method of claim 1, wherein the blood sample is selected from the group consisting of whole blood, serum, and plasma. ### Claim 3 (depends on 1) The method of claim 1, wherein the DKK1 level is determined by detecting the DKK1 protein in the serum. ### Claim 4 (depends on 3) The method of claim 3, wherein the DKK1 protein is detected by immunoassay. ### Claim 5 (depends on 4) The method of claim 4, wherein the immunoassay is an ELISA. ### Claim 6 (depends on 4) The method of claim 4, wherein the immunoassay is sandwich method which uses an anti-DKK1 polyclonal antibody as a detection antibody. ### Claim 7 A method for diagnosing esophageal cancer or lung cancer in a subject, comprising the steps of: (a) obtaining a blood sample selected from the group consisting of whole blood, serum, or plasma from a subject; (b) contacting the blood sample with an antibody against DKK1 protein to determine a blood concentration of a DKK1 protein in the blood sample; (c) providing a diagnosis that the subject suffers from esophageal cancer or lung cancer if the blood concentration of DKK1 protein in the blood sample is at least 10% greater than the normal control level obtained from a population not suffering from cancer, wherein the diagnosis has a sensitivity of 63.7% and a specificity of 95.9%. ### Claim 8 (depends on 7) The method of claim 7, wherein the analyzing is by histology or histopathology. ### Claim 9 A method for determining that a subject is in need of treatment for esophageal cancer or lung cancer, comprising: (a) contacting a blood sample selected from the group consisting of whole blood, serum, or plasma from a subject with an antibody against DKK1 protein to determine a blood concentration of a DKK1 protein in the blood sample; (b) obtaining a biological sample comprising esophageal or lung tissue from the subject by surgery or biopsy if the blood concentration of DKK1 protein in the blood sample is at least 10% greater than the normal control level obtained from a population not suffering from cancer; and (c) analyzing the biological sample to determine that the subject has esophageal cancer or lung cancer, thereby determining that the subject is in need of treatment for esophageal cancer or lung cancer, wherein the method provides a diagnostic accuracy having a sensitivity of 63.7% and a specificity of 95.9%. ### Claim 10 A method for diagnosing esophageal cancer or lung cancer in a subject, comprising the steps of: (a) obtaining a blood sample selected from the group consisting of whole blood, serum, or plasma from a subject; (b) contacting the blood sample with an antibody against DKK1 protein to determine a blood concentration of a DKK1 protein in the blood sample; (c) providing a diagnosis that the subject suffers from esophageal cancer or lung cancer if the blood concentration of DKK1 protein in the blood sample is greater than a cutoff level, wherein the cutoff level is 14.7 U/ml, and said diagnosis has a sensitivity of 63.7% and a specificity of 95.9%. ### Claim 11 A kit for detecting an esophageal cancer or lung cancer expressing DKK1 protein, wherein the kit comprises: (a) an immunoassay reagent for determining a level of DKK1 protein in a blood sample, wherein the immunoassay reagent comprises an antibody against DKK1 protein; and (b) a positive control sample for DKK1, wherein the kit provides a diagnostic accuracy having a sensitivity of 63.7% and a specificity of 95.9%. ### Claim 12 (depends on 11) The kit of claim 11, wherein the positive control sample is positive for DKK1. ### Claim 13 (depends on 12) The kit of claim 12, wherein the positive control sample is liquid form.